The efficacy and safety of laparoscopic sleeve gastrectomyin patients with severe obesity complicated with HIV infection

doi:10.3877/cma.j.issn.2095-9605.2023.01.013

Abstract

Abstract:

The efficacy and safety of laparoscopic sleeve gastrectomy (SG) in 3 patients with severe obesity complicated with HIV infection were analyzed retrospectively. The preoperative body mass index (BMI) of the three patients was 43.3 kg/m², 39.1 kg/m², 36.3 kg/m² respectively, and the CD4⁺ cell count was 436 cells/μL, 122 cells/μL, and 533 cells/μL respectively. The preoperative viral load was<100 IU/mL. Three patients were discharged on the third day after operation without any postoperative complications. Six months after operation, the patient's obstructive sleep apnea hypopnea syndrome was completely relieved, glycemia and triglyceride were reduced to normal range, weight loss was 35 kg, 27 kg, 22 kg, percentage of excess weight loss (% EWL) was 60.0%, 50.2%, 52.4%, viral load was<100 IU/mL, CD4⁺ cell count was 491 cells/μL, 206 cells/μL, 572 cells/μL respectively. LSG is effective in weight loss of HIV-infected patients with severe obesity after highly effective antiretroviral therapy, which does not increase the risk of surgery, and does not affect the efficacy of antiviral drugs after surgery.

Key words: Obesity, HIV infected, Laparoscopic sleeve gastrectomy, Safety, Effectiveness

Jianpeng Huang, Junbo Yang, Shengbin Zhu, Hua Zong. The efficacy and safety of laparoscopic sleeve gastrectomyin patients with severe obesity complicated with HIV infection[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2023, 09(01): 68-71.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2023.01.013

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2023/V09/I01/68

Figures/Tables 4

References 14

[1]	de Souza TF, Madruga Neto AC, Coronel MA, et al. The First Study Evaluating Effectiveness and Safety of the Endoscopic Sleeve Gastroplasty in HIV Patients [J]. Obes Surg, 2020, 30(3): 1159-1162.
[2]	Akbari K, Som R, Sampson M, et al. The Effect of Bariatric Surgery on Patients with HIV Infection: a Literature Review [J]. Obes Surg, 2018, 28(8): 2550-2559.
[3]	Panko N, Dunford G, Lutfi R. HIV Infection Is Not a Contraindication to Laparoscopic Sleeve Gastrectomy for Morbid Obesity [J]. Obes Surg, 28(2): 464-468.
[4]	姜舒文, 马灿业, 杨帆, 等. 人类免疫缺陷病毒（HIV）病合并肥胖症患者行腹腔镜袖状胃切除术1例报道 [J/CD]. 中华肥胖与代谢病电子杂志, 2020, 6(4): 259-261.
[5]	Shor-Posner G, Campa A, Zhang G, et al. When obesity is desirable: a longitudinal study of the Miami HIV-1-infected drug abusers (MIDAS) cohort [J]. J Acquir Immune Defic Syndr, 2000, 23(1): 81-88.
[6]	中华医学会外科学分会甲状腺及代谢外科学组, 中国医师协会外科医师分会肥胖和糖尿病外科医师委员会. 中国肥胖及2型糖尿病外科治疗指南(2019版) [J]. 中国实用外科杂志, 2019, 39(4): 301-306.
[7]	中华医学会外科学分会,中华医学会麻醉学分会. 中国加速康复外科临床实践指南(2021版) [J]. 中国实用外科杂志, 2021, 41(9): 961-992.
[8]	Thompson-Paul AM, Wei SC, Mattson CL, et al. Obesity Among HIV-Infected Adults Receiving Medical Care in the United States: Data From the Cross-Sectional Medical Monitoring Project and National Health and Nutrition Examination Survey [J].Medicine (Baltimore), 2015, 94(27): e1081.
[9]	Jenkins CA, Koethe JR, Lau B, et al. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada [J]. AIDS Res Hum Retroviruses 2016, 32(1): 50-58.
[10]	Costagliola D, Martinez V, Pourcher G. Obesity in HIV-infected patients in France: prevalence and surgical treatment options [J]. J Visc Surg, 2015, 152(1): 33-37.
[11]	Damouche A, Lazure T, Avettand-Fènoël V, et al. Adipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV Infection [J]. PLoS Pathog, 2015, 11(9): e1005153.
[12]	Kassir R, Huart E, Tiffet O, et al. Feasibility of Bariatric Surgery in the HIV-Infected Patients [J]. Obes Surg, 2017, 27(3): 818-819.
[13]	Shah S, Hindley L, Hill A. Are new antiretroviral treatments increasing the risk of weight gain? [J]. Drugs, 2021, 81(3): 299-315.
[14]	Zino L, Kingma JS, Marzolini C, et al. Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV [J]. Clin Pharmacokinet, 2022, 61(5): 619-635.

序号	年龄（岁）	身高（m）	体重（kg）	BMI（kg/m²）	空腹血糖（mmol/L）	甘油三酯（mmol/L）	血压(mmHg)	病毒载量(IU/mL)	CD4⁺计数(个/μL)
1	28	1.63	115	43.3	10.8	6.61	140/92	<100	436
2	28	1.78	124	39.1	4.53	1.81	168/116	<100	122
3	34	1.70	105	36.3	4.9	1.37	171/109	<100	533

序号	年龄（岁）	身高（m）	体重（kg）	BMI（kg/m²）	空腹血糖（mmol/L）	甘油三酯（mmol/L）	血压(mmHg)	病毒载量(IU/mL)	CD4⁺计数(个/μL)
1	28	1.63	115	43.3	10.8	6.61	140/92	<100	436
2	28	1.78	124	39.1	4.53	1.81	168/116	<100	122
3	34	1.70	105	36.3	4.9	1.37	171/109	<100	533

序号	手术时间	术前体重（kg）	术后体重减轻（kg）				%EWL（%）
序号	手术时间	术前体重（kg）	1月	3月	6月	12月	1月	3月	6月	12月
1	2021年11月	115	24	30	35	37	41.2%	51.5%	60.0%	63.5%
2	2022年1月	124	13	17	27	28	24.2%	31.6%	50.2%	52.0%
3	2022年6月	105	12	20	22	/	28.6%	47.6%	52.4%	/

序号	手术时间	术前体重（kg）	术后体重减轻（kg）				%EWL（%）
序号	手术时间	术前体重（kg）	1月	3月	6月	12月	1月	3月	6月	12月
1	2021年11月	115	24	30	35	37	41.2%	51.5%	60.0%	63.5%
2	2022年1月	124	13	17	27	28	24.2%	31.6%	50.2%	52.0%
3	2022年6月	105	12	20	22	/	28.6%	47.6%	52.4%	/

序号	术前血压（mmHg）	术前空腹血糖（mmol/L）	术前甘油三酯（mmol/L）	术后血压（mmHg）				术后空腹血糖（mmol/L）				术后甘油三酯（mmol/L）
序号	术前血压（mmHg）	术前空腹血糖（mmol/L）	术前甘油三酯（mmol/L）	1月	3月	6月	12月	1月	3月	6月	12月	1月	3月	6月	12月
1	140/92	10.8	6.61	125/80	133/86	117/78	124/83	5.42	5.47	5.13	5.36	2.45	1.73	1.58	1.62
2	168/116	4.53	1.81	140/90	140/90	130/90	130/95	5.62	5.61	5.39	5.11	1.64	2.23	1.05	0.98
3	171/109	4.9	1.37	152/93	148/94	168/103		5.65	5.43	5.78	/	1.15	1.46	1.23	/

Please choose a citation manager

Content to export